Related Experiment Videos
The use of pamidronate in hypertrophic pulmonary osteoarthropathy (HPOA)
D Speden1, F Nicklason, H Francis
1Department of Oncology, Royal Hobart Hospital, Tasmania.
Australian and New Zealand Journal of Medicine
|June 1, 1997
Abstract
Background:
Hypertrophic pulmonary osteoarthropathy (HPOA) secondary to bronchogenic carcinoma can be associated with severe, disabling pain which is not always responsive to conventional treatment.
Aim:
To report on the use of pamidronate to control resistant pain in HPOA in three cases.
Methods:
A retrospective review of reported pain, chest X-ray and radionuclide bone scans was made.
Results:
Pain relief was achieved in all three cases together with reduced radiolabel uptake in two cases.
Conclusions:
Pamidronate appears to be an effective therapy for HPOA. Further investigation is warranted.